Compare Unity Software Inc (U) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unity Software Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Unity Software Inc trades at $29.79 (market cap $13.01B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.
| U | XBI | |
|---|---|---|
Market Cap | $13.01B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $49.47 | $164.28 |
52-Week Low | $17.13 | $85.16 |
Enterprise Value | $13.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unity Software (U) trades at $29.87, up 3.04% today, showing bullish technical momentum above key support levels. The company maintains strong revenue of $1.85B with improving gross margins at 62.79%, though net losses persist at -$402.77M. Recent Unity 7 platform announcements and AI integration focus signal strategic growth initiatives. Analyst consensus remains strongly bullish with 69% buy ratings and $36.50 price target, representing 22% upside potential from current levels.
Unity presents a growth opportunity with improving financial trends and strong institutional support, but faces execution risks in profitability turnaround. The stock's elevated valuation multiples (P/S 6.61, EV/EBITDA 134.62) require sustained revenue growth justification. Near-term catalyst includes Q2 2026 earnings on August 5, where analysts expect EPS of $0.24 after recent misses.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
